Search
Rizatriptan
go.drugbank.com/drugs/DB00953ApprovedInvestigationalRizatriptan is a second-generation triptan and a selective 5-HT1B and 5-HT1D receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disinte...
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSulesomab
go.drugbank.com/drugs/DB13976ApprovedMarket product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Salts: Technetium Tc-99m sulesomabFlurothyl
go.drugbank.com/drugs/DB08969ApprovedWithdrawnIt was formerly used to induce convulsions as a alternative to electroshock therapy.
Axitinib
go.drugbank.com/drugs/DB06626ApprovedInvestigationalIt is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative. … Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).
Molsidomine
go.drugbank.com/drugs/DB09282ApprovedWithdrawnMolsidomine is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones.
Larazotide
go.drugbank.com/drugs/DB05645InvestigationalAn octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.
Rifabutin
go.drugbank.com/drugs/DB00615ApprovedInvestigationalA broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
Categories: Antiinfectives for Systemic Use, Drugs for Acid Related DisordersRoquinimex
go.drugbank.com/drugs/DB11366ExperimentalIts effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.
Elsubrutinib
go.drugbank.com/drugs/DB18850InvestigationalWith Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State). … Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants
STI-1499
go.drugbank.com/drugs/DB16487InvestigationalSTI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.
Categories: Experimental Unapproved Treatments for COVID-19